ARC 1.0 team receive Fanconi Anaemi funding boost
Published on August 18, 2021
Fanconi anaemia is a rare genetic disorder associated with multiple birth defects, increased risk of leukaemia and solid tumours, and progressive aplastic anaemia which is a serious condition that occurs when the body stops producing enough blood cells.
With support from the Fanconi Anaemia Research Fund, the team at the Animal Replacement Centre (ARC) at Queen Mary University London have developed a model using human cells that mimic Fanconi Anaemia cells and have discovered potential mechanisms that may explain why Fanconi Anaemia patients develop such aggressive oral tumours, and how these cancerous cells are able to become enriched over time.
“We have applied to the Fanconi Anaemia Research Fund for further funding to use our model to test existing drugs against these cells. We have also identified new targets that enhance tumour formation potential that we can block, thus reducing cancer cell aggressiveness and may be a good target to use in combination with existing cancer therapies,” Professor Mike Philpott, the ARC.
You can take action for animals, by uniting with us now!
Too many animals continue to suffer in laboratories rather than enjoying the comfort and security of a happy home. Our work is funded entirely by your generous support, so please make a donation today to help us free animals from laboratories for good.
